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Incidence of sudden cardiac death (SCD) in end-stage renal disease (ESRD) remains high. Limited data is available about whether
implantable cardioverter-deﬁbrillators (ICDs) can prevent arrhythmic death in patients with chronic kidney disease (CKD). The
purpose of this retrospective study was to determine the impact of CKD on all-cause and sudden cardiac death in ICD recipients.
We evaluated 441 consecutive patients who underwent ICD implantation at our center between 1994 and 2002. We found that
mortality rate was higher in patients with eGFR < 60mL/min and those with ESRD on hemodialysis (43%, n = 69/162 and 54%,
n = 12/22, resp.) than in patients with eGFR ≥ 60mL/min (23%, n = 58/257; P<. 0005). The SCD rate was also higher in the
patients with ESRD (50%) than in CKD patients not on dialysis (10.2%; P<. 0005). Mortality rate for single-chamber ICDs was
56.8% in comparison with dual-chamber ICDs (38.1%) and for biventricular ICDs (5.0%) (P<. 0005).
1.Introduction
Approximately 4.5% of the adult US population (8 million
adults) suﬀers from CKD [1]. Among the CKD patients,
the highest mortality rate is in those who have ESRD on
dialysis with an estimate of 224.5 deaths/1000 patient-years
[2]. The single largest cause of death amongst ESRD patients
on hemodialysis is sudden cardiac death due to arrhythmic
mechanism, as 54.6% die of a cardiac arrest and 8.8% die
of a cardiac arrhythmia [3]. Furthermore, the rate of cardiac
arrest increases progressively in relation to the duration of
dialysis therapy [3]. Despite this extremely high arrhythmic
mortality rate, currently there is no eﬀective intervention to
prevent cardiac arrest in these patients. ICD implantation
may decrease risk of sudden cardiac death in this cohort of
patients.
Recently, multiple randomized trials have established
the beneﬁt of implantable cardioverter-deﬁbrillators (ICDs)
in improving survival in high-risk cardiac patients [4].
However, the randomized trials excluded patients with
ESRD and included only a minority of patients with mild
to moderate CKD [5–8]. Therefore, there is limited data
available on the role of ICD in preventing sudden cardiac
death in ESRD patients. Also, little is known about the
impact of CKD in determining all-cause and sudden cardiac
death in the patients who undergo ICD implantation.
The beneﬁt of cardiac resynchronization therapy with
ICD as compared to medical therapy alone has been shown
in advanced heart failure (HF) patients [9]. However, no
data is available on the relative impact of diﬀerent types
of pacing with ICD on long-term survival in the patients
with advanced renal failure. The purpose of this study
was to analyze the eﬀect of CKD on mortality in ICD
recipients.
2.MaterialsandMethods
2.1. Patient Population. In this retrospective review, we
evaluated consecutive patients who underwent ICD implan-
tationatSt.JohnHospitalfrom1994to2002.Weobtainedan
approval from the Investigational Board Review committee
of St John Hospital and Medical Center for the collection
and publication of data. For the purpose of this study,2 Cardiology Research and Practice
the patients were divided into three groups based on
severity of renal dysfunction, derived from KDOQI (Kidney
Disease Outcomes Quality Initiative) classiﬁcation [10]:
eGFR ≥ 60mL/min; eGFR < 60mL/min; ESRD undergoing
hemodialysis.
2.2. Study Protocol. T h es t u d yw a sa p p r o v e db yt h eS t .J o h n
Hospital’s Institutional Review Board. The enrolled subjects
had ICD implantation based on the following criteria based
on diﬀerent randomized control trials. (1) Nonsustained VT
in patients with coronary artery disease (CAD), previous
myocardial infarction (MI), left ventricular (LV) dysfunc-
tion, and ejection fraction (EF) <35% who had induced
sustained monomorphic VT that was nonsuppressible with
anti-arrhythmic drug, (Multicenter Automatic Deﬁbrillation
Implantation Trial investigation: MADIT) [5]. (2) EF ≤30%
in patients with a history of MI (MADIT II) [11]. (3) VF or
sustained VT with syncope, or sustained VT with an LVEF
<40% and severe symptoms (syncope, near syncope, CHF,
angina) suggestive of hemodynamic compromise, (Antiar-
rhythmics Versus Implantable Deﬁbrillators, AVID criteria)
[12]. (4) Syncope of unknown origin in CAD patients,
and severe LV dysfunction who had inducible sustained
monomorphic VT with hemodynamic compromise at EP
study [13]. Estimated measurement of their glomerular ﬁl-
tration rate (eGFR/GFR) was obtained using Cockroft-Gault
Formula. Lowest value of serum creatinine was used for
calculating the eGFR obtained from the preprocedure blood
work closest in time to device implantation. The patients
were followed up in the outpatient clinic until September
2004.Themortalityinformationwasobtainedfromavariety
of sources including the records from the hospital, physician
oﬃce,nursinghome,andthesocialsecuritydeathindex.The
information was extracted using a structured form. Mode of
death was classiﬁed as cardiac-sudden (arrhythmic), cardiac
nonsudden, noncardiac, and unknown. Sudden cardiac
death (SCD) was deﬁned as a sudden unexpected pulseless
condition of likely cardiac etiology. If unwitnessed, SCDs
were those in which patients were found dead within 24
hours of having last been seen alive and in normal state of
health[14].Eachpatientdeathwasreviewedbyacardiologist
and a nephrologist. Patients were carefully evaluated for any
history of withdrawal from dialysis prior to their death and
none of the 12 patients who had as SCD were removed from
dialysis nor missed a dialysis session prior to their cardiac
arrest.
2.3.StatisticalAnalysis. Continuousvariableswereexpressed
as mean ± standard error (SE) and compared using
unpaired t-test or ANOVA, as appropriate. Categorical
variables were expressed as frequency (%) and compared
by Chi-Square analysis. Kaplan-Meier analysis was con-
ducted to evaluate survival diﬀerences between groups.
Multivariate logistic regression was performed to determine
predictors of mortality. A P value of <.05 was considered
statistically signiﬁcant. All statistical analyses were per-
formed using SPSS statistical software (SPSS 12.0, Chicago,
IL).
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Figure 1: Kaplan-Meier (K-M) survival analysis based on stages of
kidney dysfunction. The Log Rank statistic for the K-M Survival
analysis was 25.71 (P<. 00005). For patients with GFR <
60mL/min (n = 162), mean survival time (±SE) was 60.3 ± 4.7
months (CI 51.0, 69.5) and median survival time was 49.2 ± 5.8
months (CI 37.7, 60.7). For patients with GFR ≥ 60mL/min (n =
257), mean survival was 85.9 ± 4.3 months (CI 77.4, 94.3); since
survival rate did not drop below 50% during the observation
period, no median could be calculated. For ESRD patients on
hemodialysis (n = 22), mean survival was 37.8 ± 7.7m o n t h s( C I
22.8, 52.8) and median survival was 19.1 ±1.8 (CI 15.6, 22.7).
3. Results
The clinical characteristics of the 441 patients (340 men
(77%); mean age 66.8 ± 0.6 (±SE) years), based on the
patient’s level of kidney dysfunction, are shown in Table 1.
Not unexpectedly, the age of the three groups diﬀered
(ANOVA, P<. 0005). Patients with GFR < 60mL/min
were older than each of the other groups (Scheﬀep o s th o c
analysis, P<. 0035), and the proportion of Caucasians was
higher (Chi Square, P = .041). Diabetes was most prevalent
in patients on hemodialysis (P = .028). Serum magnesium
and potassium were highest in patients undergoing dialysis
(ANOVA, P<. 0005). A higher proportion of patients
on hemodialysis were receiving amiodarone (40.9%; Chi
Square, P = .012), possibly because many of these patients
were noted to have atrial ﬁbrillation (P = .049). Patients on
hemodialysis were receiving ACE-Is/ARBs at the lowest rate
(59.1%; P = .025).
3.1. Long-Term Survival Analysis. The overall survival was
85.9 ± 4.3, 60.3 ± 4.7, and 37.8 ± 7.7 months for those
with GFR ≥ 60mL/min, those with GFR of <60mL/min,
and ESRD patients on hemodialysis, respectively (Log rank
statistic 25.71; P<. 00005). Shown in Figure 1 are the
Kaplan-Meier survival curves for these three groups. The
death rate was highest in the patients on hemodialysisCardiology Research and Practice 3
Table 1: Characteristics of the study population. Groups based on eGFR or being on hemodialysis.
GFR ESRD on
≥60mL/min <60mL/min hemodialysis
(n = 257) (n = 162) (n = 22) t-test or χ2
Characteristics Mean ± SE or % (n) P
Age (yr) 62.6 ±0.87 3 .7 ±0.76 5 .0 ±2.9 <.0005
Male Gender 78.6 (202) 75.9 (123) 68.2 (15) NS
Caucasian Race 72.0 (185) 82.7 (134) 72.7 (16) .041
Hypertension 70.8 (182) 70.8 (114) 90.9 (20) NS
Diabetes Mellitus 28.8 (74) 27.2 (44) 54.5 (12) .028
Ischemic Heart Disease 77.0 (151) 83.2 (109) 88.9 (16) NS
Ejection Fraction (%) 26.6 ± 0.8 25.2 ± 0.8 25.0 ± 2.6 NS
eGFR (mL/min) 93.6 ± 2.0 44.7 ± 0.8 10.3 ± 0.4 <.0005
Creatinine (mg/dl) 1.02 ± 0.02 1.52 ± 0.04 7.14 ± 0.30 <.0005
Magnesium (mg/dl) 1.75 ± 0.02 1.77 ± 0.02 2.01 ± 0.5 <.0005
Potasium (mEq/L) 4.16 ± 0.03 4.28 ± 0.43 4.68 ± 0.14 <.0005
Amiodarone 15.6 (40) 18.5 (30) 40.9 (9) .012
Atrial ﬁbrillation 19.8 (51) 28.4 (46) 36.4 (8) .049
DFT > 20 Joules 35.3 (88) 27.7 (43) 66.7 (2) .129
Beta-blockers 46.7 (120) 40.7 (66) 63.6 (14) .103
ACEIs/ARBs 78.6 (202) 69.1 (112) 59.1 (13) .025
Reason for ICD NS
Primary prevention 51.3 (132) 56.7 (92) 54.5 (12)
Secondary prevention 48.8 (125) 43.5 (70) 45.4 (10)
Type of ICD .112
Single Chamber 30.0 (77) 39.5 (64) 36.4 (8)
Dual Chamber 59.1 (152) 45.7 (74) 54.5 (12)
Biventricular 10.9 (28) 14.8 (24) 9.1 (2)
NS: P>. 05.
(54.5%), followed by patients with GFR < 60 (42.6%), and
lowest in those with GFR ≥ 60 (22.6%; Chi Square, P<
.0005). Median survival time was 49.2 months for patients
with GFR ≥ 60mL/min and 19.1 months for patients on
hemodialysis.
Figure 2 shows the incidence of diﬀerent modes of death
in the three groups. The rate of sudden cardiac death was
signiﬁcantly higher for patients with ESRD on hemodialysis
(50.0%)thanforthosewithGFR<60andGFR ≥60mL/min
(10.1% versus 10.3%, resp.; P = .001).
3.2. Univariate Analysis. The univariate predictors of mor-
tality were age at ICD implantation, GFR, serum creatinine
and magnesium, Caucasian race, taking beta blockers, taking
ACE-Is/ARBs, reason ICD was implanted, and type of ICD
(Table 2).
3.3. Multivariate Analysis. The results of multivariate logis-
tic regression analysis, given in the right-hand columns
of Table 2, revealed that age, decreased eGFR, diabetes
mellitus, the absence of beta blockers, absence of ACE
inhibitors/ARBs, and the type of ICD were independent
predictors of all-cause mortality. As compared to the
biventricular ICD, single-chamber and dual chamber ICDs
were independently associated with decreased survival. The
highest odds ratio was generated for the single chamber ICD
(10.499; 95% CI 3.238–34.045). The data was adjusted for
gender, ischemic heart disease, ejection fraction, primary
or secondary prevention, amiodarone, race, HTN, atrial
ﬁbrillation, magnesium, potassium, creatinine, deﬁbrillation
threshold 20 joules and above, QRS over 150mSec, and type
of revascularization.
4. Discussion
The main ﬁnding of the study is that chronic kidney disease
is independently linked to increased all-cause mortality
in ICD recipients. Second, the incidence of SCD in this
cohort of patients is signiﬁcantly high in those with ESRD
on hemodialysis as compared to those with less advanced
CKD. Third, the clinical factors which independently predict
increased mortality in the patients who undergo ICD
implantation include increased age, decreased estimated
GFR, absence of beta blockers, diabetes mellitus, absence
of ACE/ARBs, and type of ICD. The absence of beta-
blockers and ACE inhibitors identiﬁes patients with
persistent hypotension, which highlights severe end-stage
cardiomyopathy. These observations extend the previous4 Cardiology Research and Practice
Table 2: Mortality Predictors in Univariate and Multivariate Analyses.
Alive Dead t-test or
(n = 302) (n = 139) χ2 Logistic Regression
Predictors Mean ± SE or % (n) P OR 95% CI
Age (yr) 65.2 ±0.77 0 .3 ±0.9 <.0005 1.034 1.005–1.064
eGFR (mL/min) 78.1 ±2.25 7 .0 ±2.6 <.0005 .986 .975–.997
Creatinine (mg/dl) 1.38 ±0.07 1.80 ±0.14 .008
Magnesium (mg/dl) 1.75 ±0.01 1.81 ±0.03 .019
Caucasian Race 73.2 (221) 82.0 (114) .044
Diabetes Mellitus 27.2 (82) 34.5 (48) .114 2.094 1.129–3.883
Beta-blockers 53.3 (161) 28.1 (39) <.0005 .342 .190–.614
ACEIs/ARBs 78.5 (237) 64.7 (90) .002 .515 .269–.985
Reason for ICD .005
Primary prevention 57.9 (175) 43.8 (61)
Secondary prevention 42.1 (127) 56.2 (78)
Type of ICD <.0005
Single Chamber 23.2 (70) 56.8 (79) 10.499 3.238–34.045
Dual Chamber 61.3 (185) 38.1 (53) 4.232 1.326–13.505
Biventricular 15.6 (47) 5.0 (7) 1.0
data that has shown that these variables are associated with
mortality in HF patients [15] .T h es u r v i v a lb e n e ﬁ to fI C D
type is unlikely to be due to chance, since the proportion of
each type implanted in the 3 kidney function categories did
not diﬀer (P = .112).
This study conﬁrms previous ﬁndings that the common-
est mode of death in ESRD patients is SCD [3]. Bleyer
et al. reported that the incidence of sudden cardiac death
increases by 50% on Monday for patients dialyzing on
Monday, Wednesday, and Friday [16]. Despite this extremely
high incidence of arrhythmic deaths in this population, there
are limited eﬀective preventive strategies available. Recently,
data from multiple, large-scale, randomized-controlled trials
have shown that ICDs are eﬀective in reducing mortality
in high-risk cardiac patients [5–8]. However, all the major
trials excluded patients with advanced CKD or ESRD [5–
8]. At this point, majority of cardiomyopathy patients with
advanced CKD or ESRD are undergoing ICD implantation
without any substantial evidence of survival beneﬁt. Since
CKDisaverystrongandindependentpredictorofmortality,
the risk-beneﬁt ratio of an invasive and expensive therapy
such as ICD needs to be speciﬁcally studied in CKD patients,
before extrapolating the ﬁndings of the ICD trials to this
population.
Herzog et al. used the Medicare database to retrospec-
tivelystudyover6000ESRDpatientssurvivingcardiacarrest.
They reported a 42% reduction of death risk in the patients
who received ICDs (as compared to those who did not) over
aﬁ v e - y e a rp e r i o d[ 17]. This data supports the use of ICDs in
the secondary prevention of sudden cardiac death in ESRD
patients. However, the majority (85%) of the ESRD patients
hospitalized after the cardiac arrest die in one year [10]. The
current study showed a higher mortality rate in patients who
hadICDimplantationforsecondarypreventionascompared
to those with primary prevention ICD. These observational
ﬁndings support the hypothesis that implanting an ICD for
primary prevention in a cardiomyopathy patient, already on
the continuum of CKD, may be more eﬀective before they
have had a cardiac arrhythmia or arrest (Table 2).
Based on the ﬁndings of our study, further prospective
studies will deﬁne the role of the ICD implantation and
whether a certain type of ICD will beneﬁt renal failure
patients more in prevention of sudden cardiac death. The
results are consistent with the recent report of Wase et al.
who studied 95 patients who underwent ICD implantation
and found higher mortality in the patients with an eGFR <
60cc/min as compared to those with an eGFR ≥ 60cc/min
[18].
The exact causes of this alarmingly high total and
arrhythmic mortality in CKD patients are multifactorial.
First, CKD alone is an independent risk factor for coro-
nary artery disease (CAD) [19]. Second, the traditional
cardiovascular risk factors, that is, hypertension (which may
be accompanied by left ventricular hypertrophy), smoking,
diabetes, metabolic syndrome, dyslipidemia, and older age,
are highly prevalent in CKD patients [20, 21]. Third, there
are possible additional risk factors that are relatively unique
to patients with moderate to severe CKD. These include
decreased excretion of uremic toxins, anemia, increased
calcium intake, abnormalities in bone mineral metabolism,
hyperhomocysteinemia,and/oran“increasedinﬂammatory-
poor nutrition” state [22]. And ﬁnally, CKD patients have
a higher propensity towards increased sympathetic activ-
ity and arrhythmias [23]. Higher deﬁbrillation thresholds
(DFTs), in CKD patients receiving ICD, have been reported
as compared to those without CKD [18]. Among the
patients with higher DFTs who undergo ICD implantation,
the majority die of arrhythmias [24]. This observationCardiology Research and Practice 5
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Figure 2: Cause-speciﬁc mortality according to varying levels of
renal dysfunction. For the 3 categories of renal dysfunction, cause-
speciﬁcmortalityisdepicted.Asexpected,suddencardiacdeathwas
the major cause of death in ESRD patients on dialysis (50.0% versus
10.1% (GFR < 60mL/min) versus 10.3% (GFR ≥ 60mL/min), Chi
Square P = .010). Number at the top of each bar is the mortality
rate; number within the bar is the n per group. The Unknown
category was reserved for those patients whose cause of death could
not be determined. Thus, adding the numbers within the bars for
three groups will not equal the n given in Table 1.
might explain the high incidence of arrhythmic deaths in
ESRD patients who undergo ICD implantation, despite the
presence of ICDs.
This survival data after adjusting for potential con-
founders in multivariate analysis suggests that compared to
single chamber ICDs, dual chamber and biventricular ICDs
(patients receiving cardiac resynchronization therapy) are
independently associated with improved survival (Table 2).
The beneﬁts of dual chamber pacing (i.e., pacing both the
right atrium and/or right ventricle) compared to single
chamber (i.e., right ventricle) could be explained by the
following potential beneﬁts associated with dual chamber
pacing: (1) presence of chronic atrial ﬁbrillation possibly
aﬀecting survival in recipients of single chamber ICDs, (2)
the detrimental eﬀect of chronic right ventricle (RV) pacing
(which is more likely to be avoided or minimized with AAI
pacing mode in a dual-chamber ICD as compared to a
single-chamber ICD), triggering mechanical dyssynchrony
between the left ventricle and right ventricles [25], and (3)
in some studies, atrial pacing has reduced the frequency
of atrial ﬁbrillation [26]. Biventricular ICD was identiﬁed
as a stronger predictor of improved survival, as compared
to dual-chamber ICD. It is likely that this diﬀerence is
due to the detrimental eﬀect of RV pacing, which may
cause dys-synchrony between the ventricles [25]. RV pacing
causes the RV to contract before the left ventricle (LV),
simulating the eﬀects of left bundle branch block (LBBB).
Pacing-induced loss of ventricular synchrony worsens heart
failure (HF) [27]. Correction of ventricular dyssynchrony
in patients with HF via biventricular pacing (or cardiac
resynchronization therapy) improves patient survival and
other clinical outcomes [28].
The study had the following limitations. First, part of
thestudydatawascollectedretrospectively.Second,although
every eﬀort was made to collect the lowest serum creatinine
level available in the absence of acute renal failure, creatinine
may not have been at baseline in some patients. And third,
intracardiac electrogram data was not available to conﬁrm
the mode of death. However, a clinically validated deﬁnition
of sudden cardiac death was used [14].
5. Conclusions
InpatientsundergoingICDimplantation,thestageofkidney
dysfunction is a strong predictor of mortality. The ESRD
patients on hemodialysis had a higher incidence of sudden
cardiac death (50%) than CKD patients not on dialysis
(10.2%).Otherpredictorsofmortalityincludeincreasedage,
ICD type, diabetes mellitus, absence of beta blocker, and
absence of ACE inhibitors/ARBs. ICD insertion for primary
prevention was more eﬀective in averting fatal events than
insertion for secondary prevention in this nonrandomized
study. This study underscores the need for conducting large-
scale, randomized, controlled trials, to prospectively evaluate
the beneﬁts and risks of ICD therapy in patients with
cardiomyopathy and kidney dysfunction.
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